Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DetectedX is an Australian digital health and medical imaging education company that provides a cloud-based radiology learning and diagnostic improvement platform for clinicians, trainees, universities, and imaging providers. The company emerged from the University of Sydney and builds on the BREAST reader assessment work developed by its founders. Its products deliver interactive, image-based self-assessment modules, lectures, quizzes, peer benchmarking, and CME/CPD-accredited training designed to improve interpretation accuracy in breast and chest imaging. DetectedX markets breast cancer, lung cancer, COVID-19, dust disease, and image quality training content, and also offers a customizable platform called ImageDX for image-based medical education. The company appears to be a commercial-stage private business focused on radiology training, quality assurance, and diagnostic performance improvement rather than therapeutic drug development.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DetectedX.